When administered with monotherapeutic checkpoint blockade, tumor‐inoculated mice treated with H11‐HLE exhibited comparable antitumor activity to those treated with anti‐CTLA‐4 antibodies, yet without the induction of colitis. This evidence concerns the gene CTLA4 and colitis.